期刊文献+

损伤相关模式分子对人肝癌HepG2细胞增殖能力的影响

Effect of DAMPs on proliferation of human liver cancer HepG2 cells
下载PDF
导出
摘要 目的 观察在DAMPs诱导下人肝癌HepG2细胞增殖能力的变化.方法 将HepG2细胞分为对照组和实验组(10、20、40、80 μl DAMPs处理的HepG2细胞);MTT比色法检测HepG2细胞的增殖能力;实时荧光定量PCR法检测IL-6 mRNA表达的变化;Western Blot法检测HepG2细胞IL-6蛋白的表达情况.结果 HepG2细胞随着DAMPs剂量的递增及时间的延长增殖能力逐渐增强,呈现明显的量效-时效关系,在剂量40 μl,作用时间36 h时细胞增殖能力达到最强,差异有统计学意义(P〈0.01);选取作用时间为36 h,随着DAMPs剂量的递增,实时定量PCR法检测到HepG2细胞IL-6 mRNA分别为95.55±4.47,171.80±6.60,453.30±14.47,610.59±12.70,441.04±18.91,差异有统计学意义(P〈0.01);Western Blot法检测HepG2细胞IL-6蛋白的表达分别为1.47、2.07、2.74、3.44、3.00,差异有统计学意义(P〈0.01).结论 DAMPs在一定剂量及时间内促进人肝癌HepG2细胞增殖,并且呈现明显的量效-时效关系. Objective To study the changes in DAMPs-induced proliferation of liver cancer HepG2 ceils. Methods HepG2 cells were divided into control group, and DAMPs-treated groups (10, 20, 40 and 80 L). MTT assay was applied to investigate the proliferation of HepG2 cells. The expression of IL-6 mRNA in HepG2 cells was detected by using quantitative RT-PCR. Results MTT result demonstrated that the proliferation of HepG2 cells had a dose- and time-dependent with DAMPs. The proliferation of HepG2 cells reached to peak when the dose of DAMPs was 40 L for 36 h of culture (P〈0. 01). Quantitative RT-PCR revealed that the expression of IL-6 mRNA was 95.55 ±4. 47, 171.80 ± 6.60, 453.30 ± 14.47, 610. 59 ± 12. 70 and 441.04± 18. 91 respectively when HepG2 cells were exposed to DAMPs (10, 20, 40 and 80 L) at 36 h (P〈0. 01), while thelL-6 pro- tein level in HepG2 cells was 1.47, 2. 07, 2.74, 3.44, 3.00 respectively (P〈0. 01). Conclusion DAMPs may promote the proliferation of HepG2 cells in a dose-and time-dependent manner.
出处 《腹部外科》 2013年第6期423-426,共4页 Journal of Abdominal Surgery
关键词 肝细胞 DAMPS IL-6 HEPG2细胞 细胞增殖 Carcinoma, hepatocellular DAMPs IL-6 HepG2 cells Cell proliferation
  • 相关文献

参考文献2

二级参考文献39

  • 1王文清,邱双健,吴志全,樊嘉,叶胜龙,李新丰,叶超平.肝细胞癌根治性切除术后复发转移与血清转化生长因子-β1的关系[J].中华实验外科杂志,2005,22(1):100-101. 被引量:18
  • 2[1]Oka M,Iizuka N,Yamamoto K,Gondo T,Abe T,Hazama S,Akitomi Y,Koishihara Y,Ohsugi Y,Ooba Y,Ishihara T,Suzuki T.The influence of interleukin -6 on the growth of human esophageal cancer cell lines.J Interferon Cytokine Res 1996; 16:1001-1006
  • 3[2]Miki S,Iwano M,Miki Y,Yamamoto M,Tang B,Yokokawa K,Sonoda T,Hirano T,Kishimoto T.Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.FEBS Lett 1989; 250:607-610
  • 4[3]Lee JD,Sievers TM,Skotzko M,Chandler CF,Morton DL,McBride WH,Economou JS.Interleukin-6 production by human melanoma cell lines.Lymphokine Cytokine Res 1992; 11:161-166
  • 5[4]Siegall CB,Schwab G,Nordan RP,FitzGerald DJ,Pastan Ⅰ.Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.Cancer Res 1990; 50:7786-7788
  • 6[5]Watson JM,Sensintaffar JL,Berek JS,Martinez-Maza O.Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.Cancer Res 1990;50:6959-6965
  • 7[6]Bataille R,Jourdan M,Zhang XG,Klein B.Serum levels of interleukin 6,a potent myeloma cell growth factor,as a reflect of disease severity in plasma cell dyscrasias.J Clin Invest 1989;84:2008-2011
  • 8[7]Tsukamoto T,Kumamoto Y,Miyao N,Masumori N,Takahashi A,Yanase M.Interleukin-6 in renal cell carcinoma.J Urol1992; 148:1778-1781; discussion 1781-1782
  • 9[8]Seguchi T,Yokokawa K,Sugao H,Nakano E,Sonoda T,Okuyama A.Interleukin-6 activity in urine and serum in patients with bladder carcinoma.J Urol1992; 148:791-794
  • 10[9]Yanagawa H,Sone S,Takahashi Y,Haku T,Yano S,Shinohara T,Ogura T.Serum levels of interleukin-6 in patients with lung cancer.Br J Cancer 1995; 71:1095-1098

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部